Tosoian JJ, Singhal U, Davenport MS, et al. - Findings demonstrate a significant association of MyProstateScore (MPS) with GG≥2 cancer across all PI-RADS scores, in patients who underwent multiparametric MRI (mpMRI) and biopsy. A significantly better performance of MPS, than that of PSAD, in ruling out GG≥2 cancer was evident in the PI-RADS 3 population. These results indicate that MPS testing has a complementary role in patients that have undergone mpMRI.

• This study included 540 patients who underwent mpMRI and biopsy with MPS available, to assess the complementary role of urinary MPS testing and mpMRI and evaluate results in patients with equivocal mpMRI.

• For PI-RADS 3, PI-RADS 4, and PI-RADS 5, the reported prevalence of GG≥2 cancer was 13%, 56%, and 87%, respectively.

• In males with GG≥2 cancer, significantly higher MPS [median 44.9] was evident compared with those with negative or GG1 biopsy [median 29.2] in the overall population and when stratified by PI-RADS score.

• The AUC for predicting GG≥2 cancer, in the PI-RADS 3 population (n=121), was 0.55, 0.62, and 0.73 for PSA, PSAD, and for MPS, respectively.

• MPS offered the highest net clinical advantage across all pertinent threshold probabilities.